Trials Sponsors Conditions Drugs Pricing

Conditions

Solid Tumor, Adult

Keywords

Next Generation SequencingPersonalized TherapyMolecular Tumor Board

Outcome Measures

Primary Outcomes (1)

ORR(Objective Response Rate)
ORR is the percentage of participants with best overall response of complete response (CR), partial response (PR). Response categories: CR, PR, SD (stable disease), PD (progressive disease) Criteria on which physicians determined therapy response also will be captured by using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 to evaluate.
Up to three months

Secondary Outcomes (3)

PFS (Progression Free Survival), calculated from various time points
Up to two years
OS (Overall Survival), calculated from various time points
Duration of time from the start of treatment to date of death, assessed up to 2 years
ADR (Adverse Drug Reaction)
30 days after last dose.

Study Arms (1)

Advanced Refractory Solid Tumors

Patients with advanced refractory solid tumors receive personalized therapy with the guidance of Molecular Tumor Board after the NGS(next generation sequencing).

Other: Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing

Interventions

Personalized therapy model with Molecular Tumor Board and Next Generation SequencingOther

This study is to observe this therapy model outcomes

Advanced Refractory Solid Tumors

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The objective is to describe in a real-world advanced refractory solid tumors population. First of all, this study will be carried out as a retrospective, observational review of patients who clinically diagnosed as advanced refractory solid tumors received personalized therapy with the guidance of MTB (molecular tumor board) after the NGS (next generation sequencing). Then, the investigators prospective observation personalized therapy plan which the MTB recommends for patients who clinically diagnosed as advanced refractory solid tumors according to the inclusion and exclusion criteria.

You may qualify if:

Sponsors & Collaborators

Tianjin Medical University Second Hospital
Otherlead

Study Sites (1)

Tianjin Medical Unversity Second Hospital

Tianjin, Tianjin Municipality, 300211, China

MeSH Terms

Interventions

High-Throughput Nucleotide Sequencing

Intervention Hierarchy (Ancestors)

Sequence AnalysisGenetic TechniquesInvestigative Techniques

Study Officials

Haitao Wang
Tianjin Medical Unversity Second Hospital
PRINCIPAL INVESTIGATOR

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: OTHER
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 24, 2019

First Posted

April 29, 2019

Study Start

June 1, 2017

Actual (reported)

Primary Completion

June 30, 2019

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

Advanced Refractory Solid Tumors

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

Advanced Refractory Solid Tumors

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations